Among the many things CFOs have been trying to wrap their heads around these past few weeks is whether to revise down their December marks before releasing them soon. A consensus seems to have emerged on that issue this month. The next question is, what do we do about March 31? The situation is still rapidly developing, the US might be considered in the late part of the early stages of its response, and it is unlikely that much forward-looking input will be available, possibly not even by May.
My article, published Friday (link above), takes a look at some of the considerations I’ve heard so far, and includes some best practice advice from the experts at Duff & Phelps.
Take a look and get in touch if you have further thoughts.
Secondaries: Surely the potential opportunity GP-led secondaries can provide troubled assets has already crossed many a mind. My colleagues at Secondaries Investor argue here that, after the sector’s precipitous rise in status in recent years, and the claim by many that it represents a “win-win-win”, may now be put to the test. Adam Le writes that for GP-led practitioners, it’s time to prove your worth.
Hope you had a safe, news-free weekend.
Email prepared by Graham Bippart
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: 
